ES2138976T3 - Uso de analogos o antagonistas de interleucina-10 para tratar la toxicidad inducida por endotoxinas o superantigenos. - Google Patents

Uso de analogos o antagonistas de interleucina-10 para tratar la toxicidad inducida por endotoxinas o superantigenos.

Info

Publication number
ES2138976T3
ES2138976T3 ES92917650T ES92917650T ES2138976T3 ES 2138976 T3 ES2138976 T3 ES 2138976T3 ES 92917650 T ES92917650 T ES 92917650T ES 92917650 T ES92917650 T ES 92917650T ES 2138976 T3 ES2138976 T3 ES 2138976T3
Authority
ES
Spain
Prior art keywords
interleukin
antagonists
analogs
induced toxicity
treat endotoxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92917650T
Other languages
English (en)
Inventor
Waal Malefyt Rene De
Maureen Howard
Di-Hwei Hsu
Hiroshi Ishida
Anne O'garra
Hergen Spits
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2138976T3 publication Critical patent/ES2138976T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

SE PRESENTA UN METODO PARA EL TRATAMIENTO DE CONMOCIONES SEPTICAS O CONMOCIONES TOXICAS QUE CONSISTE EN ADMINISTRAR UNA CANTIDAD EFECTIVA DE INTERLEUCINA-10.
ES92917650T 1991-08-06 1992-08-06 Uso de analogos o antagonistas de interleucina-10 para tratar la toxicidad inducida por endotoxinas o superantigenos. Expired - Lifetime ES2138976T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74212991A 1991-08-06 1991-08-06

Publications (1)

Publication Number Publication Date
ES2138976T3 true ES2138976T3 (es) 2000-02-01

Family

ID=24983602

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92917650T Expired - Lifetime ES2138976T3 (es) 1991-08-06 1992-08-06 Uso de analogos o antagonistas de interleucina-10 para tratar la toxicidad inducida por endotoxinas o superantigenos.

Country Status (17)

Country Link
EP (2) EP0541214A3 (es)
JP (3) JPH07502019A (es)
KR (1) KR100271197B1 (es)
AT (1) ATE187336T1 (es)
AU (1) AU678137B2 (es)
CA (1) CA2115060C (es)
CZ (1) CZ281796B6 (es)
DE (1) DE69230403T2 (es)
DK (1) DK0600970T3 (es)
ES (1) ES2138976T3 (es)
FI (1) FI940519L (es)
GR (1) GR3032167T3 (es)
HU (1) HU224437B1 (es)
NO (1) NO315409B1 (es)
PT (1) PT600970E (es)
SK (1) SK282947B6 (es)
WO (1) WO1993002693A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3801193A (en) * 1992-03-20 1993-10-21 Schering Corporation Use of interleukin-10 to induce the production of interleukin-1 receptor antagonist
EP0667789A1 (en) * 1992-09-18 1995-08-23 Schering Corporation Restoration of immunocompetency to t helper cells in hiv infected patients
AU6000894A (en) * 1993-02-01 1994-08-29 Michel Goldman Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
IL110413A0 (en) * 1993-07-26 1994-10-21 Schering Corp Agonists and antagonists of human interleukin-10
US6159937A (en) * 1994-07-05 2000-12-12 Steeno Research Group A/S Immunomodulators
US5753218A (en) * 1996-05-03 1998-05-19 Schering Corporation Method for treating inflammation
WO2002066069A1 (en) * 2001-02-20 2002-08-29 Kansai Technology Licensing Organization Co., Ltd. Remedies for inflammatory/tumor diseases
AR046833A1 (es) * 2003-11-10 2005-12-28 Schering Corp Anticuerpos anti-interleuquina-10
CN102711829B (zh) 2009-11-30 2016-03-16 生物测试股份公司 治疗系统性红斑狼疮(sle)的人源化抗il-10抗体
EP2986990B1 (en) 2013-03-20 2018-08-15 F.Hoffmann-La Roche Ag Specific detection of rat antibodies in mouse serum

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
DE69013011T2 (de) * 1989-12-20 1995-02-23 Schering Corp., Kenilworth, N.J. Bcrf1-proteine als inhibitoren von interferon-g(g).

Also Published As

Publication number Publication date
EP0541214A2 (en) 1993-05-12
PT600970E (pt) 2000-05-31
SK282947B6 (sk) 2003-01-09
NO315409B1 (no) 2003-09-01
CA2115060C (en) 2003-05-06
DE69230403D1 (de) 2000-01-13
JP2004250454A (ja) 2004-09-09
DK0600970T3 (da) 2000-05-29
HU224437B1 (hu) 2005-09-28
DE69230403T2 (de) 2000-05-11
FI940519A7 (fi) 1994-02-04
GR3032167T3 (en) 2000-04-27
NO940370L (no) 1994-02-04
CZ281796B6 (cs) 1997-02-12
JPH07502019A (ja) 1995-03-02
WO1993002693A2 (en) 1993-02-18
CZ24394A3 (en) 1995-01-18
HUT66865A (en) 1995-01-30
JP2008013573A (ja) 2008-01-24
NO940370D0 (no) 1994-02-04
FI940519A0 (fi) 1994-02-04
EP0600970A1 (en) 1994-06-15
CA2115060A1 (en) 1993-02-18
WO1993002693A3 (en) 1993-07-22
FI940519L (fi) 1994-02-04
EP0600970B1 (en) 1999-12-08
ATE187336T1 (de) 1999-12-15
HU9400314D0 (en) 1994-05-30
AU678137B2 (en) 1997-05-22
EP0541214A3 (en) 1993-09-08
AU2441192A (en) 1993-03-02
KR100271197B1 (ko) 2000-11-01
SK12994A3 (en) 1994-12-07

Similar Documents

Publication Publication Date Title
NO934383L (no) Roentgenkontrastmiddel
CY1118334T1 (el) Χρηση δαπτομυκινης
ES2032016T3 (es) Un procedimiento para la produccion de las 13, 14-ceto-pgfs.
ES2045110T3 (es) Mejoras en o relacionadas con antagonistas de leucotrienos.
ES2114620T3 (es) Composiciones antitumorales que contienen derivados del taxano.
BR8707672A (pt) Pirazolinas inseticidas
ES2132105T3 (es) 2-aminometil-cromanos como principios activos en farmacos para el tratamiento de enfermedades del sistema nervioso central.
ES2079063T3 (es) Utilizacion de analogos de vitamina d en el tratamiento del acne.
ATE133534T1 (de) Antimikrobizides gemisch
RU94041950A (ru) Использование соединений ряда 3-аролоксипропиламинов в лечении недержания
ES2188795T3 (es) Agentes antimicrobianos benzoxacina.
ES2150933T3 (es) Inhibidores de la proteasa vih utiles para el tratamiento del sida.
ES2052463T1 (es) Antihipercolesterolemicos.
ES2038650T3 (es) Procedimiento para preparar una composicion farmaceutica que comprende 3'-desoxitimidin-2'-eno-(3'-desoxi-2',3'-dideshidrotimidina) para tratar pacientes infectados con retrovirus.
ES2156120T3 (es) Derivados arilamidicos.
ES2134801T3 (es) Monohidrato de hidrocloruro de tiagabina cristalina, su preparacion y su uso.
ES2108698T3 (es) Liposomas exentos de sustancias activas, para el tratamiento de aterosclerosis.
ES2170798T3 (es) Benzopiranos y su uso como agentes terapeuticos.
SE8107298L (sv) Mikrobicida/mikrobistatiska kompositioner och anvendning derav
FI940519A0 (fi) Interleukiini-10-analogien tai -antagonistien käyttö endotoksiinin taisuperantigeenin indusoiman toksisuuden hoitamiseksi
ES2038064B1 (es) Instalacion portatil de vacunacion aviar.
ES2086528T3 (es) Nuevos compuestos biciclicos sustituidos con amino.
ES2090530T3 (es) Produccion de peces mejorada.
ES2122085T3 (es) Combinacion antibiotica.
ES2194129T3 (es) Compuestos farmaceuticos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 600970

Country of ref document: ES